← Back to Search

Other

Verdiperstat for Amyotrophic Lateral Sclerosis

Phase 2 & 3

Waitlist Available

Led By Merit Cudkowicz, MD

Research Sponsored by Merit E. Cudkowicz, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 weeks

Awards & highlights

Study Summary

This trial will last as long as there are investigational products available to be evaluated and participants willing to be enrolled.

Eligible Conditions

ALS (Amyotrophic Lateral Sclerosis)

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Disease Progression as Assessed by the ALSFRS-R-Slope

Mortality Even Rate

Secondary outcome measures

Muscle Strength

Number of Participants That Experienced Death or Death Equivalent

Respiratory Function

Side effects data

From 2022 Phase 2 & 3 trial • 167 Patients • NCT04436510

28%

Nausea

21%

Headache

20%

Insomnia

19%

Fall

19%

Constipation

17%

Muscular weakness

16%

Fatigue

13%

Neuromyopathy

10%

Dizziness

10%

Dysphagia

10%

Tension headache

10%

Decreased appetite

Blood thyroid stimulating hormone increased

Diarrhoea

Salivary hypersecretion

Dyspnoea

Urinary tract infection

Anxiety

Oedema peripheral

Arthralgia

Back pain

Urine odour abnormal

Cough

Dysarthria

Pain in extremity

Febrile neutropenia

Respiratory failure

Pulmonary embolism

Amyotrophic lateral sclerosis

Ileus

Failure to thrive

Deep vein thrombosis

Dehydration

B-cell lymphoma

Acute respiratory failure

Abdominal pain

Hepatic enzyme abnormal

Aphasia

Cerebral infarction

Bacteraemia

Bacterial sepsis

COVID-19

COVID-19 pneumonia

Sudden death

Hip fracture

100%

80%

60%

40%

20%

Study treatment Arm

Matching Placebo

Verdiperstat

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: VerdiperstatExperimental Treatment1 Intervention

Verdiperstat is administered twice daily p.o. for 24 weeks.

Group II: Matching PlaceboPlacebo Group1 Intervention

Matching placebo is administered twice daily p.o. for 24 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Verdiperstat

2019

Completed Phase 3

~610

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Biohaven Pharmaceuticals, Inc.Industry Sponsor

47 Previous Clinical Trials

36,968 Total Patients Enrolled

2 Trials studying Amyotrophic Lateral Sclerosis

22 Patients Enrolled for Amyotrophic Lateral Sclerosis

Merit E. Cudkowicz, MDLead Sponsor

7 Previous Clinical Trials

2,687 Total Patients Enrolled

7 Trials studying Amyotrophic Lateral Sclerosis

2,687 Patients Enrolled for Amyotrophic Lateral Sclerosis

Merit Cudkowicz, MDPrincipal InvestigatorMassachusetts General Hospital

8 Previous Clinical Trials

2,504 Total Patients Enrolled

8 Trials studying Amyotrophic Lateral Sclerosis

2,504 Patients Enrolled for Amyotrophic Lateral Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has there been extensive research on Verdiperstat in the past?

"At the moment, there are two different clinical trials involving Verdiperstat that are ongoing. Out of those two, one is in Phase 3. Even though a majority of the Verdiperstat trials are based in Ann Arbor, Michigan, there are a total of 68 medical centres running trials for this medication."

Answered by AI

Are there still available slots left for participants in this research?

"Presently, this study is not looking for more patients to enroll. This trial was originally posted on July 28th 2020 and was last updated on June 25th 2022. There are a total of 135 trials actively searching for patients with amyotrophic lateral sclerosis and 2 trials for Verdiperstat that are also looking for patients."

Answered by AI

How many people are helping researchers by taking part in this clinical trial?

"As of right now, this trial isn't looking for any new patients. The study was originally posted on July 28th, 2020 and was last edited on June 25th, 2022. For patients looking for other trials, there are 135 studies for amyotrophic lateral sclerosis enrolling patients and 2 trials for Verdiperstat that are actively searching for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Merit E. Cudkowicz, MD 2020. "HEALEY ALS Platform Trial - Regimen B Verdiperstat". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04436510.